Company Filing History:
Years Active: 2009-2012
Title: The Innovations of Stephan Sollberg
Introduction
Stephan Sollberg is a notable inventor based in Schwerin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of vascular endothelial growth factor (VEGF) mutants. With a total of two patents to his name, Sollberg's work focuses on advancing medical treatments for chronic wounds.
Latest Patents
Sollberg's latest patents include innovative approaches to VEGF. The first patent details the use of proteolysis resistant active VEGF, where the alanine at amino acid position 111 is replaced by proline. Additionally, the arginine at amino acid position 110 may be substituted with another amino acid. This invention also encompasses derivatives of VEGF, nucleic acids, expression systems, and medicaments aimed at treating chronic wounds. The second patent reiterates similar findings, emphasizing the potential of these VEGF mutants in medical applications.
Career Highlights
Stephan Sollberg is currently associated with Bayer Innovation GmbH, where he continues to push the boundaries of medical research. His work has garnered attention for its potential to improve treatment options for patients suffering from chronic wounds. Sollberg's innovative mindset and dedication to research have positioned him as a key figure in his field.
Collaborations
Throughout his career, Sollberg has collaborated with esteemed colleagues such as Sabine Eming and Thomas Krieg. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.
Conclusion
Stephan Sollberg's contributions to the field of biotechnology, particularly through his patents on VEGF mutants, highlight his innovative spirit and commitment to improving medical treatments. His work continues to inspire advancements in the treatment of chronic wounds.